These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Hemostatic abnormalities associated with cancer and its therapy. Glassman AB Ann Clin Lab Sci; 1997; 27(6):391-5. PubMed ID: 9433535 [TBL] [Abstract][Full Text] [Related]
26. Hemostasis and thrombosis in critically ill children. Kenet G; Strauss T; Kaplinsky C; Paret G Semin Thromb Hemost; 2008 Jul; 34(5):451-8. PubMed ID: 18956285 [TBL] [Abstract][Full Text] [Related]
27. Antiplatelet and anticoagulant therapy in patients with advanced heart failure. Lip GY; Chung I Thromb Res; 2005; 116(4):275-7. PubMed ID: 16038710 [No Abstract] [Full Text] [Related]
28. Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Serebruany VL; Malinin AI; Jerome SD; Lowry DR; Morgan AW; Sane DC; Tanguay JF; Steinhubl SR; O'connor CM Am Heart J; 2003 Oct; 146(4):713-20. PubMed ID: 14564328 [TBL] [Abstract][Full Text] [Related]
29. [Diagnosis and treatment of coagulation disorders]. Esnaola-Rojas MM Rev Neurol; 1999 Dec 16-31; 29(12):1290-300. PubMed ID: 10652759 [TBL] [Abstract][Full Text] [Related]
31. Left ventricular thrombus and the incidence of thromboembolism in patients with congestive heart failure: can clinical factors identify patients at increased risk? Katz SD J Cardiovasc Risk; 1995 Apr; 2(2):97-102. PubMed ID: 7606657 [TBL] [Abstract][Full Text] [Related]
32. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Jafri SM; Ozawa T; Mammen E; Levine TB; Johnson C; Goldstein S Eur Heart J; 1993 Feb; 14(2):205-12. PubMed ID: 8449196 [TBL] [Abstract][Full Text] [Related]
33. Increased activation of the coagulation and fibrinolytic systems leads to hemorrhagic complications during left ventricular assist implantation. Livingston ER; Fisher CA; Bibidakis EJ; Pathak AS; Todd BA; Furukawa S; McClurken JB; Addonizio VP; Jeevanandam V Circulation; 1996 Nov; 94(9 Suppl):II227-34. PubMed ID: 8901751 [TBL] [Abstract][Full Text] [Related]
34. Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. Yano Y; Ohmori T; Hoshide S; Madoiwa S; Yamamoto K; Katsuki T; Mitsuhashi T; Mimuro J; Shimada K; Kario K; Sakata Y Eur Heart J; 2008 Jul; 29(14):1729-38. PubMed ID: 18270211 [TBL] [Abstract][Full Text] [Related]
35. Safety of recombinant human factor XIII in a cynomolgus monkey model of extracorporeal blood circulation. Ponce R; Armstrong K; Andrews K; Hensler J; Waggie K; Heffernan J; Reynolds T; Rogge M Toxicol Pathol; 2005; 33(6):702-10. PubMed ID: 16243775 [TBL] [Abstract][Full Text] [Related]
36. Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. Sbarouni E; Bradshaw A; Andreotti F; Tuddenham E; Oakley CM; Cleland JG Am Heart J; 1994 Mar; 127(3):607-12. PubMed ID: 8122609 [TBL] [Abstract][Full Text] [Related]